重组人脑钠肽治疗顽固性心力衰竭的疗效与安全性分析(1)
摘 要 目的：探討重组人脑钠肽治疗顽固性心力衰竭的疗效与安全性。方法：纳入2018年6月—2019年6月江西省萍乡市芦溪县人民医院收治的顽固性心力衰竭患者60例，随机分为观察组和对照组各30例。对照组给予硝酸甘油10 mg+5%葡萄糖注射液48 ml持续泵注；观察组给予重组人脑钠肽0.5 mg+0.9%氯化钠注射液50 ml，先以1.5 mg/kg静脉冲击，后以0.0075 mg·kg-1？min-2的速度连续静脉泵入；两组均连续治疗3 d。比较两组患者治疗效果、治疗前后客观指标监控结果以及用药期间不良反应发生情况。结果：观察组总有效率为96.67%，高于对照组的80.00%(P<0.05)。观察组患者治疗后收缩压(SBP)、舒张压(DBP)、心率(HR)和呼吸频率(RR)水平均低于对照组(P均<0.05)，血氧饱和度(SpO2)水平则高于对照组(P<0.05)。两组用药期间不良反应总发生率对比差异无统计学意义(P>0.05)。结论：重组人脑钠肽治疗顽固性心力衰竭疗效显著，且不会增加不良反应，值得临床推荐。
关键词 顽固性心力衰竭；重组人脑钠肽；疗效；安全性
中图分类号：R541.6 文献标志码：A 文章编号：1006-1533(2020)12-0025-03
Analysis of efficacy and safety of recombinant human brain natriuretic peptide in the treatment of intractable heart failure
XIA Lihua(The First Internal Medicine Department of People’s Hospital of Luxi County， Pingxiang City， Jiangxi Province 337200， China)
ABSTRACT Objective： To investigate the efficacy and safety of recombinant human brain natriuretic peptide in the treatment of intractable heart failure. Methods： From June 2018 to June 2019， 60 patients with intractable heart failure were enrolled in the People’s Hospital of Luxi County， Pingxiang City， Jiangxi Province， and randomly divided into an observation group and a control group with 30 cases each. The control group was given continuous pump injection of nitroglycerin 10 mg + 5% glucose injection 48 ml； and the observation group was given recombinant human brain natriuretic peptide 0.5 mg + 0.9% sodium chloride injection 50 ml， firstly intravenously injected 1.5 mg/kg， then continuously intravenously pumped at a speed of 0.0075 mg？kg-1？min-2； both groups were treated for 3 days. The therapeutic effect， the monitoring results of objective indexes before and after treatment and the occurrence of adverse reactions were compared between the two groups. Results： The total effective treatment rate of the observation group was 96.67%， which was higher than that of the control group 80.00%(P<0.05). The levels of SBP， DBP， HR and RR of the observation group were lower than those of the control group((all P <0.05). And the level of SpO2 of the observation group was higher than that of the control group(P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05). Conclusion： Recombinant human brain natriuretic peptide is effective in the treatment of intractable heart failure， and does not significantly increase adverse reactions， which is worthy of clinical recommendation., 百拇医药(夏丽华)
关键词 顽固性心力衰竭；重组人脑钠肽；疗效；安全性
中图分类号：R541.6 文献标志码：A 文章编号：1006-1533(2020)12-0025-03
Analysis of efficacy and safety of recombinant human brain natriuretic peptide in the treatment of intractable heart failure
XIA Lihua(The First Internal Medicine Department of People’s Hospital of Luxi County， Pingxiang City， Jiangxi Province 337200， China)
ABSTRACT Objective： To investigate the efficacy and safety of recombinant human brain natriuretic peptide in the treatment of intractable heart failure. Methods： From June 2018 to June 2019， 60 patients with intractable heart failure were enrolled in the People’s Hospital of Luxi County， Pingxiang City， Jiangxi Province， and randomly divided into an observation group and a control group with 30 cases each. The control group was given continuous pump injection of nitroglycerin 10 mg + 5% glucose injection 48 ml； and the observation group was given recombinant human brain natriuretic peptide 0.5 mg + 0.9% sodium chloride injection 50 ml， firstly intravenously injected 1.5 mg/kg， then continuously intravenously pumped at a speed of 0.0075 mg？kg-1？min-2； both groups were treated for 3 days. The therapeutic effect， the monitoring results of objective indexes before and after treatment and the occurrence of adverse reactions were compared between the two groups. Results： The total effective treatment rate of the observation group was 96.67%， which was higher than that of the control group 80.00%(P<0.05). The levels of SBP， DBP， HR and RR of the observation group were lower than those of the control group((all P <0.05). And the level of SpO2 of the observation group was higher than that of the control group(P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05). Conclusion： Recombinant human brain natriuretic peptide is effective in the treatment of intractable heart failure， and does not significantly increase adverse reactions， which is worthy of clinical recommendation., 百拇医药(夏丽华)
参见：首页 > 医疗版 > 疾病专题 > 心血管科 > 心力衰竭 > 顽固性心力衰竭